Abstract 408P
Background
Sarcomas are a heterogeneous group of uncommon malignancies that are rarely encountered in most general oncology clinics and most general oncologists have very little experience in dealing with them. The Asian Sarcoma Consortium (ASC) is an international study group of oncologists specializing in sarcomas. The group has decided to start a Sarcoma Preceptorship Program. Its goal is increased awareness of the multidisciplinary approach in sarcomas. Objective is to conduct a program evaluation using the first 2 levels of the Kirkpatrick Model, involving Level 1 – focusing on satisfaction surveys of the participants and Level 2 – focusing on amount of information gained through a pre-test and a post-test.
Methods
Activities included didactic lectures, multidisciplinary case discussions and a summative multidisciplinary case presentation at the conclusion. Evaluation was done using satisfaction survey forms and a pre- and post-test. Novartis did their own survey & results were included in analysis, but had no direct participation in conduct of program.
Results
31 persons mostly Oncologists from University/Government Hospitals participated. 50% were consultants. Satisfaction surveys were optimistic, with ASC forms showing high level of satisfaction for the time and scope. Satisfaction level was high when helpfulness of topics was considered. Faculty response showed similar trends. Ratings remained consistent when the Novartis evaluation data were included. Areas for improvement included time management, content, language barriers and inconsistencies in facilitation. Results from pre-test and post-test showed test scores lower in post-test. Coefficient of Test reliability showed that pre-test was highly reliable but not post-test, the causes included external factors like time allotment for the post-test and presence of distractions.
Conclusions
The program was successful in terms of participant and faculty satisfaction. Results were supported by Novartis data. Certain areas for improvement were identified and recommendations were made.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asian Sarcoma Consortium.
Funding
Asian Sarcoma Consortium Novartis Pharma.
Disclosure
F.Y. Gracieux Jr.: Honoraria (self), RTD Speaker: Roche Philippines; Honoraria (self), Conference Speaker, RTD Speaker: Novartis Philippines; Honoraria (self), Webinar Moderator; RTD Speaker: Boehringer Ingelheim; Honoraria (self), Conference Speaker: GSK Philippines; Honoraria (self), Conference Speaker: Beacon Bangladesh; Honoraria (self), Conference Speaker; RTD Speaker: Roche Malaysia; Honoraria (self), Conference Speaker: Roche Myanmar.
Resources from the same session
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract